Thallion to present preliminary results of Phase 2 SHIGATEC trial at VTEC 2012
Thallion Pharmaceuticals (TSX:TLN) has announced that it is preparing to report preliminary results of its Phase 2 SHIGATEC trial, evaluating Shigamabs as a treatment for Shiga toxin-producing E. coli (STEC) infection, at the upcoming 8th International Symposium on Shiga Toxin (Verocytotoxin)-Producing Escherichia coli Infections (VTEC 2012), which takes place in Amsterdam, the Netherlands. The oral presentation, entitled “SHIGATEC: A phase II study evaluating Shigamabs in STEC-infected children,” is expected to be given during the morning session on May 9th.
CEO Dr. Allan Mandelzys said, “the VTEC conference is the leading international forum on Shiga toxin-producing bacterial infections and provides an excellent platform for the first dissemination of the un-blinded data.”
Thallion is the only company working on a treatment for STEC. Shigamabs is designed to neutralize the two types of Shiga toxin secreted by pathogenic E. coli well before any infection leads to a life-threatening kidney disease called hemolytic uremic syndrome (HUS).
Symptoms of STEC infection include severe stomach cramps, diarrhea, which is often bloody, and vomiting. If there is fever, it usually is not very high. Most patients’ symptoms improve within five to seven days, but some patients go on to develop HUS, usually about a week after the diarrhea starts.